CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vedanta Biosciences, a late clinical-stage biopharmaceutical company developing microbiome-based oral therapies for gastrointestinal diseases, today announced securing $60 million in funding, a clinical update for its pivotal Phase 3 RESTORATiVE303 study of VE303 for the prevention of recurrent C. difficile infection, and new appointments to its Board of Directors. The funding includes a $40 million financing round led by existing investors AMR Action Fund and